In recent years, the debate over net price transparency (NPT) has intensified with organisations leading calls for greater transparency of net prices in the pharmaceutical sector. In a study funded by Merck Sharp & Dohme, an expert panel coordinated by CRA developed evidence on the impact of greater NPT on innovative medicines in Europe.
Patient burden associated with acute & chronic resistant infections
Inspiring stakeholders to take action on antimicrobial resistance (AMR) starts with communicating the current and future burden of...